DOPF

DOPF
Clinical data
Other names	DOPF; 2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine
Identifiers
	IUPAC name 2-[4-(3-fluoropropyl)-2,5-dimethoxyphenyl]ethanamine;
PubChem CID	163192484;
ChemSpider	129558527;
CompTox Dashboard (EPA)	DTXSID001337046 ;
Chemical and physical data
Formula	C14H22FNO2
Molar mass	255.333 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(CCCF)c(cc1CC(C)N)OC;
	InChI InChI=1S/C14H22FNO2/c1-10(16)7-12-9-13(17-2)11(5-4-6-15)8-14(12)18-3/h8-10H,4-7,16H2,1-3H3; Key:UIHSFMYQJAKMHD-UHFFFAOYSA-N;

Substituted amphetamine designer drug

Pharmaceutical compound

2,5-Dimethoxy-4-(3-fluoropropyl)amphetamine (DOPF) is a designer drug from the amphetamine and DOx families. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (K_i) of 9 nM at the serotonin receptor 5-HT_2A but is not known to have been tested in humans.^[1]

References

^ Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion [Phenethylamine From structure to function] (in German). Nachtschatten Verlag AG. p. 778-780. ISBN 978-3-03788-700-4.

This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information.